Prothena Corporation plc
PRTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$483.74M
Close$
$3.40
60.7% downside
Current Fair Value
60.7% downsideOvervalued by 60.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $483.74 Million |
|---|---|
| Enterprise Value | $163.57 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.53 |
| Beta | -0.31 |
| Outstanding Shares | 53,708,000 |
Return
| Return on Equity | -48.36% |
|---|---|
| Return on Assets | -43.21% |
| Return on Invested Capital | -27.23% |
Valuation & Multiples
| P/E Ratio | -3.29 |
|---|---|
| PEG | 2.13 |
| Price to Sales | 8.64 |
| Price to Book Ratio | 1.73 |
| Enterprise Value to Revenue | 2.82 |
| Enterprise Value to EBIT | -1.89 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$808,909
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$425,833
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 47.36% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.29%▼ 86.98% |
|---|---|
| Total Invested | $1.55M▼ 99.66% |
| Investors Holding | 6▼ 187.00% |
ESG Score
No data
About Prothena Corporation plc
7 employees
CEO: Gene Kinney Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and r...